WVE - Wave Life Sciences Ltd. (WVE) Q4 2023 Earnings Call Transcript

2024-03-06 12:03:05 ET

Wave Life Sciences Ltd. (WVE)

Q4 2023 Earnings Call Transcript

March 06, 2024 08:30 AM ET

Company Participants

Kate Rausch - Vice President, Investor Relations & Corporate Affairs

Paul Bolno - President & Chief Executive Officer

Anne-Marie Li-Kwai-Cheung - Chief Development Officer

Kyle Moran - Chief Financial Officer

Conference Call Participants

Timur Ivannikov - Raymond James

Salim Syed - Mizuho

Joon Lee - Truist

Joseph Schwartz - Leerink Partners

Luca Issi - RBC Capital

Andrew Fein - H.C. Wainwright

Presentation

Operator

Good morning, and welcome to Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. As a reminder, this call is being recorded and webcast.

I'll now turn the call over to Kate Rausch, Vice President, Investor Relations and Corporate Affairs. Please go ahead.

Kate Rausch

Thank you, operator. Good morning, and thank you for joining us today to discuss our recent business progress and review Wave's fourth quarter and full year 2023 financial results. Joining me today with prepared remarks are Dr. Paul Bolno, President and Chief Executive Officer, Kyle Moran, Chief Financial Officer and Anne-Marie Li-Kwai-Cheung, Chief Development Officer. The press release issued this morning is available on the Investors section of our website, www.wavelifesciences.com.

Before we begin, I would like to remind you that discussions during this conference call will include forward-looking statements. These statements are subject to several risks and uncertainties that could cause our actual results to differ materially from those described in these forward-looking statements. The factors that could cause actual results to differ are discussed in the press release issued today and in our SEC filings. We undertake no obligation to update or revise any forward-looking statement for any reason.

I'd now like to turn the call over to Paul.

Paul Bolno

Thanks, Kate. Good morning, and thank you all for joining us on today's call. I will open with comments on our recent progress and continued execution on our strategy. Next Anne-Marie will provide an update on our three ongoing clinical trials. Before opening up the call for questions, Kyle will review our financials....

For further details see: